参考文献:

[ 1 ] 　Yamazaki A , Shirato H , Nishioka T ,et al . Reduction of latecomplications after irregularly shaped four2field whole pelvicradiot herapy using computed tomographic simulation comparedwit h parallel2opposed whole pelvic radiot herapy[J ] . Jpn J ClinOncol ,2000 ,30 (4) :1802184.

[ 2 ] 　Mutic S , Malyapa RS , Grigsby PW,et al . PET2guided IMRTfor cervical carcinoma wit h positive para2aortic lymph nodes2adose2escalation t reatment planning study[J ] . Int J Radiat On2col Biol Phys ,2003 ,55 (1) :28235.

[ 3 ] 　D’Souza WD , Ahamad AA , Iyer RB , et al . Feasibility of doseescalation using intensity2modulated radiot herapy in post hys2terectomy cervical carcinoma[J ] . Int J Radiat Oncol Biol Phys ,2005 ,61 (4) :106221070.

[ 4 ] 　Chen MF , Tseng CJ , Tseng CC , et al . Clinical outcome inpost hysterectomy cervical cancer patient s t reated wit h concur2rent Cisplatin and intensity2modulated pelvic radiot herapy :comparison wit h conventional radiot herapy [ J ] . Int J RadiatOncol Biol Phys , 2007 ,67 (5) :143821444.

[ 5 ] 　Grigsby P , Winter K, Komaki R ,et al . Long2term follow2upof RTOG 88205 : twice2daily external irradiation wit h brachy2t herapy for carcinoma of t he cervix[J ] . Int J Radiat Oncol BiolPhys ,2002 ,54 (1) :51257.

[ 6 ] 　Kavanagh BD , Segreti EM , Koo D ,et al . Long2term local con2t rol and survival after concomitant boost accelerated radiot her2apy for locally advanced cervix cancer [ J ] . Am J Clin Oncol ,__ 2001 ,24 (2) :1132119.

[ 7 ] 　Mat suura K, Tanimoto H , Fujita K,et al . Early clinical out2comes of 3D2conformal radiot herapy using accelerated hyper2f ractionation wit hout int racavitary brachyt herapy for cervicalcancer [J ] . Gynecol Oncol ,2007 ,104 (1) :11214.

[ 8 ] 　Milutin B ,Jovan B ,Zoran K. Rectal dosimet ry in int racavitaryapplications of cervix carcinoma : Comparison of two met hods[J ] . Archive ofOncology ,2002 ,10 (4) :2532259.

[ 9 ] 　Beriwal S , Kim H , Heron DE , et al . Comparison of 2D vs.3D dosimet ry for Rotte ’Y’ applicator high dose rate brachyt he2rapy for medically inoperable endomet rial cancer [ J ] . TechnolCancer Res Treat , 2006 ,5 (5) :5212527.

[ 10 ] Wachter2Gerstner N , Wachter S , Reinstadler E ,et al . Bladderand rect um dose defined f rom MRI based t reatment planningfor cervix cancer brachyt herapy : comparison of dose2volumehistograms for organ contours and organ wall , comparisonwit h ICRU rectum and bladder reference point [ J ] . Radiot herOncol ,2003 ,68 (3) :2692276.

[11 ] Mutic S , Grigsby PW, Low DA , et al. PET2guided three2dimen2sional treatment planning of intracavitary gynecologic implant s[J ] .Int J Radiat Oncol Biol Phys ,2002 ,52 (4) :110421110.

[12 ] Tacev T , PtáckováB , Strnad V. Californium2252 (252Cf) versusconventional gamma radiation in the brachytherapy of advanced cer2vical carcinoma long2term t reatment result s of a randomized study[J ] . Strahlenther Onkol ,2003 ,179 (6) :3772384.

[13 ] Lorvidhaya V , Chitapanarux I , Sangruchi S ,et al . Concurrentmitomycin C , 52fluorouracil , and radiot herapy in t he t reatmentof locally advanced carcinoma of t he cervix : a randomized t rial[J ] . Int J Radiat Oncol Biol Phys ,2003 ,55 (5) :122621232.

[ 14 ] Ohara K, Tanaka YO , Tsunoda H ,et al . Preliminary estima2tion of t reatment effect on uterine cervical squamous cell carci2noma in terms of tumor regression rate : comparison betweenchemoradiot herapy and radiot herapy alone [ J ] . Radiat Med ,2005 ,23 (1) :25229.

[ 15 ] Me2Yeon Lee , Hong2Gyun Wu , Kyubo Kim ,et al . Concurrentradiot herapy wit h paclitaxel/ carboplatin chemot herapy as a de2finitive t reatment for squamous cell carcinoma of t he uterinecervix[J ] . Gynecologic Oncology ,2007 ,104 (1) :95299.

[ 16 ] Rein DT , Kurbacher CM , Breidenbach M ,et al . Weekly car2boplatin and docetaxel for locally advanced primary and recur2rent cervical cancer : a phase I study[J ] . Gynecol Oncol ,2002 ,87 (1) :982103.

[ 17 ] Windschall A , Ott OJ , Sauer R ,et al . Radiation t herapy andsimultaneous chemot herapy for recurrent cervical carcinoma[J ] . St rahlent her Onkol ,2005 ,181 (8) :5452550.

[ 18 ] Shibata K, Kikkawa F , Suzuki Y, et al . Usefulness of preop2erative chemoradiation in locally advanced cervical carcinoma[J ] . Gynecol Obstet Invest ,2004 ,57 (2) :93299.

[ 19 ] Ryu HS , Chun M , Chang KH ,et al . Postoperative adjuvantconcurrent chemoradiot herapy improves survival rates for high2risk , early stage cervical cancer patient s [ J ] . Gynecol Oncol ,2005 ,96 (2) :4902495.

[ 20 ] Maneo A , Colombo A , Landoni F , et al . Treatment of stageⅢB cervical carcinoma. A comparison between radiot herapy ,concurrent chemo2radiot herapy and neoadjuvant chemot herapy[J ] . Minerva Ginecol ,2005 ,57 (2) :1412152.

[ 21 ] Saito T , Takehara M , Lee R ,et al . Neoadjuvant chemot hera2py wit h cisplatin , aclacinomycin A , and mitomycin C for cervi2cal adenocarcinoma22a preliminary study [ J ] . Int J GynecolCancer ,2004 ,14 (3) :4832490.

[ 22 ] Tzioras S , Pavlidis N , Paraskevaidis E ,et al . Effect s of differ2ent chemot herapy regimens on survival for advanced cervicalcancer : systematic review and meta2analysis [J ] . Cancer TreatRev ,2007 ,33 (1) :24238.

[ 23 ] Timot headou E , Gore ME. Neoadjuvant chemot herapy for lo2cally advanced cervical cancer [J ] . Eur J Cancer ,2003 ,39 (17) :241922421.

[ 24 ] Münstedt K, Johnson P , von Georgi R ,et al . Consequences ofinadvertent , suboptimal primary surgery in carcinoma of t he u2terine cervix[J ] . Gynecol Oncol ,2004 ,94 (2) :5152520.[编辑:周永红;校对:马福元]